Loading...
NASDAQ: ME
23andMe Holding Co.
Healthcare · Medical - Diagnostics & Research
Market Cap
$15.31M
52w High
$12.76
52w Low
$0.48
P/E
-0.07
Volume
29.75M
Outstanding Shares
25.25M
Company profile
23andMe Holding Co. operates as a consumer genetics testing company.
CEOJoseph Selsavage
SectorHealthcare
IndustryMedical - Diagnostics & Research
Employees560
IPO dateNov 23, 2020
Valuation
Forward P/E—
EV/EBITDA-0.32
Enterprise value$49.27M
Stock splits
Oct 16, 20241:20
Profitability & growth
Revenue growth-37.1%
Gross margin53.33%▲16.39%vs FY2024
Operating margin-114%▲13.39%vs FY2024
ROE1,050.35%▲397.00%vs FY2024
Analyst consensus
RatingBuy
Target price$3.71▲511.91%
3
Buy
1
Hold
0
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 4, 2025
View
EPS
Actual vs estimate by quarter
Q2FY25
ActualEst.
-$2.32
-$3.15
Q1'25
ActualEst.
-$1.02
-$3.19
Q3'25
ActualEst.
-$0.00
—
Q3FY25
Next Est.
—
Revenue
Actual vs estimate by quarter
Q2FY25
ActualEst.
$44.07M
$36.41M
Q1'25
ActualEst.
$60.26M
$41.1M
Q3'25
ActualEst.
$25.42M
—
Q3FY25
Next Est.
—